EDAP TMS S.A. Reports Positive Second Quarter Earnings Results for FY 2023
August 31, 2023
☀️Earnings Overview
EDAP TMS S.A ($NASDAQ:EDAP). reported their financial results for the 2nd quarter of FY 2023, on June 30 2023. Total revenue increased by 0.9% year over year to EUR 14.3 million, but net income dropped from 1.8 million in the prior year to -4.7 million.
Stock Price
EDAP TMS S.A., a global leader in minimally invasive medical devices, reported positive second quarter earnings results for fiscal year 2023 on Thursday. The company’s stock opened at $7.8 and closed at $8.1, down by 0.1% from last closing price of 8.1. Overall, these positive financial results have made EDAP TMS S.A a strong contender in the medical device industry and investors should be encouraged by these positive earnings results. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for EDAP. More…
| Total Revenues | Net Income | Net Margin |
| 57.03 | -17.31 | -27.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for EDAP. More…
| Operations | Investing | Financing |
| -12.97 | -3.84 | 20.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for EDAP. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 95.33 | 32.11 | 1.94 |
Key Ratios Snapshot
Some of the financial key ratios for EDAP are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.4% | 77.9% | -21.3% |
| FCF Margin | ROE | ROA |
| -29.4% | -10.6% | -8.0% |
Analysis
At GoodWhale, we have done a comprehensive analysis of EDAP TMS S.A.’s fundamentals. Our Risk Rating has found that EDAP TMS S.A. has a high risk profile when it comes to both financial and business aspects. Additionally, our platform has identified two risk warnings in EDAP TMS S.A.’s income sheet and cashflow statement. To get a closer look at these warnings, become a registered user of GoodWhale. More…
Peers
Edap TMS SA operates in a competitive industry, where it faces a range of competitors including El.En. SpA, BATM Advanced Communications Ltd, and Theralase Technologies Inc. All of these companies are driven to develop new products, increase market share, and position themselves as leaders in the field. As such, Edap TMS SA must constantly strive to differentiate its products and services in order to remain competitive.
– El.En. SpA ($LTS:0RH2)
El.En. SpA is a leading manufacturer and distributor of laser products for the medical, industrial and research sectors. The company has a market capitalization of 960.65M as of 2023, making it one of the larger companies in its sector. Additionally, El.En. SpA has a Return on Equity of 17.74%, showing that the company is utilizing its resources to generate a healthy return for its investors. In other words, the company is doing well and is worth investing in.
– BATM Advanced Communications Ltd ($LSE:BVC)
BATM Advanced Communications Ltd is an Israeli-based company that specializes in the development of networking and cyber security solutions. It provides a wide range of solutions for telecom operators, medical institutions, defense companies, financial organizations, and more. As of 2023, the company has a market capitalization of 96.8 million dollars and a Return on Equity of 2.07%. This indicates that shareholders are benefitting from the company’s performance and that the company is financially secure. The company’s focus on developing innovative solutions for its customers has enabled it to remain competitive in the market and achieve a strong financial position.
– Theralase Technologies Inc ($TSXV:TLT)
Theralase Technologies Inc is a Canadian biotechnology company that focuses on the research, development and commercialization of light activated PhotoDynamic Compounds (PDCs) and their associated drug formulations. Theralase Technologies Inc currently has a market cap of 58.46M as of 2023, and its Return on Equity (ROE) is -113.03%. This indicates that the company is not generating enough returns from its invested capital. As a biotechnology firm, Theralase Technologies Inc has the potential to develop products with high market demand, and has the potential to realize higher returns in the future.
Summary
EDAP TMS S.A. has reported their earnings results for the second quarter of FY 2023, ending June 30 2023. Revenue increased by 0.9% from the prior year to reach EUR 14.3 million, however, net income declined from 1.8 million to -4.7 million. This could be an indication of a weaker financial performance than expected.
Investors should be mindful of this and monitor the company’s future results for further insight into its financial health. It is important to consider the company’s competitive landscape, cash flow, and liquidity when making an investing decision in EDAP TMS S.A.
Related Posts
Recent Posts
